Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.

In this third episode, we consider the challenges associated with defining and valuing digital assets. Aligning the target’s and acquiror’s views on valuation is obviously key to getting a deal done. Digital assets present some unique challenges for pharmaceutical companies more used to valuing molecules in traditional licensing or acquisition transactions. What techniques do they need to deploy to overcome this hurdle? You can also learn more by downloading our report which accompanies this podcast series.